CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 12,346	$ 6,911
Marketable securities, current	3,047	1,848
Receivables	7,685	5,747
Inventories	4,293	1,195
Other current assets	1,983	2,015
Total Current Assets	29,354	17,716
Property, plant and equipment	6,252	5,027
Goodwill	22,488	6,538
Other intangible assets	63,969	1,091
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent	510	815
Marketable securities, noncurrent	767	1,775
Other Assets, Noncurrent	6,604	2,024
Total Assets	129,944	34,986
Current Liabilities:
Short-term debt obligations	3,346	1,703
Accounts payable	2,445	1,892
Other current liabilities	12,513	7,059
Total Current Liabilities	18,304	10,654
Deferred Income Tax Liabilities, Net	6,454	19
Long-term debt, excluding current maturities	43,387	5,646
Other Liabilities, Noncurrent	10,101	4,540
Total Liabilities	78,246	20,859
Commitments and contingencies
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,568 in 2019 and 3,590 in 2018, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2019 and 2.2 billion issued in 2018	292	221
Capital in excess of par value of stock	43,709	2,081
Accumulated other comprehensive loss	(1,520)	(2,762)
Retained earnings	34,474	34,065
Less cost of treasury stock - 672 million common shares in 2019 and 576 million common shares in 2018	(25,357)	(19,574)
Total Bristol-Myers Squibb Company Shareholders' Equity	51,598	14,031
Noncontrolling interest	100	96
Total Equity	51,698	14,127
Total Liabilities and Equity	$ 129,944	$ 34,986